Ariclaim
duloxetine
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for Ariclaim has been withdrawn at the request of the marketing authorisation holder.
This EPAR was last updated on 07/08/2018
Authorisation details
| Product details | |
|---|---|
| Name |
Ariclaim
|
| Agency product number |
EMEA/H/C/000552
|
| Active substance |
duloxetine
|
| International non-proprietary name (INN) or common name |
duloxetine
|
| Therapeutic area (MeSH) |
Diabetic Neuropathies
|
| Anatomical therapeutic chemical (ATC) code |
N06AX21
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Eli Lilly Nederland B.V.
|
| Revision |
26
|
| Date of issue of marketing authorisation valid throughout the European Union |
11/08/2004
|
| Contact address |
Papendorpseweg 83 |
Product information
09/12/2016 Ariclaim - EMEA/H/C/000552 - N/0066
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Pharmacotherapeutic group
Psychoanaleptics
Therapeutic indication
Therapeutic indication
Treatment of diabetic peripheral neuropathic pain.
Ariclaim is indicated in adults.